IDiyas

For the Inventor, By the Inventor

Waltham, MA, United States of America

Michelle Lamb

USPTO Granted Patents = 13 


 

Average Co-Inventor Count = 7.1

ph-index = 4

Forward Citations = 47(Granted Patents)


Location History:

  • Belmont, MA (US) (2012)
  • Waltham, MA (US) (2009 - 2022)
  • Wilmington, DE (US) (2022)

Company Filing History:

goldMedal13 out of 1,500 
 
Astrazeneca Ab
 patents

Years Active: 2009-2022

Loading Chart...
Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents
1. 11472816 - Mcl-1 inhibitors and methods of use thereof (2022-10-18),
2. 11352369 - Pyridine and pyrimidine derivatives (2022-06-07),
3. 10889594 - MCL-1 inhibitors and methods of use thereof (2021-01-12),
4. 10717746 - Chemical compounds (2020-07-21),
5. 10196404 - MCL-1 inhibitors and methods of use thereof (2019-02-05),
6. 9845331 - Chemical compounds (2017-12-19),
7. 9840518 - MCL-1 inhibitors and methods of use thereof (2017-12-12),
8. 8901307 - Chemical compounds 251 (2014-12-02),
9. 8835465 - Pyrazolylaminopyridine derivatives useful as kinase inhibitors (2014-09-16),
10. 8486966 - 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer (2013-07-16),
11. 8324252 - Pyrazolylaminopyridine derivatives useful as kinase inhibitors (2012-12-04),
12. 8129403 - Chemical compounds (2012-03-06),
13. 7622482 - Chemical compounds (2009-11-24),

Title: Michelle Lamb: Innovator in Cancer Treatment

Introduction

Michelle Lamb is a prominent inventor based in Waltham, MA (US), known for her significant contributions to the field of cancer treatment. With a total of 13 patents to her name, she has made remarkable strides in developing innovative compounds that target various forms of cancer.

Latest Patents

Among her latest patents is a groundbreaking compound known as Mcl-1 inhibitors and methods of use thereof. This compound, identified as 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.10000]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, along with its enantiomers and pharmaceutically acceptable salts, has shown promise in treating cancer. Additionally, she has developed a series of novel pyridine and pyrimidine derivatives that inhibit CDK9, which may be beneficial in treating hyperproliferative diseases, including various types of cancer such as acute myeloid leukemia and breast cancer.

Career Highlights

Michelle Lamb currently works at AstraZeneca AB, where she continues to push the boundaries of cancer research and treatment. Her work has been instrumental in advancing the understanding of how specific compounds can be utilized in therapeutic applications.

Collaborations

Some of her notable coworkers include Alexander Hird and Tao Wang, who have collaborated with her on various projects aimed at enhancing cancer treatment methodologies.

Conclusion

Michelle Lamb's innovative work in the field of cancer treatment exemplifies the impact of dedicated inventors in the medical research community. Her contributions continue to pave the way for new therapeutic options for patients battling cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…